Buy Artesunate 50mg Online at USA

Artesunate 50 mg

Artesunate 50 mg is a water-soluble hemisuccinate derivative of artemisinin. It is unstable in neutral solution and the injectable formulation must be prepared immediately before use in 5% (w/v) sodium bicarbonate solution to produce the salt sodium artesunate. After parenteral administration, it is rapidly hydrolysed to the active metabolite dihydroartemisinin. The oral formulation is probably hydrolysed completely before entering the systemic circulation.

Artesunate has been report to clear passion in patients with severe falciparum malaria 16-25 hours after parenteral direction.

Uses of Artesunate 50mg:

Artesunate cancer Is Used Primarily As Treatment For Malaria.

Side Effects of Artesunate 50mg:

Transient And Reversible Reticulocytopaenia, Drug Fever, Rash, Bradycardia, Transient 1st-Degree Heart Block And Reversible Elevation Of Serum Transaminases.

Drug and sampling regimens.

On admission a full history was taken, a full examination was performed, and the patient was weighed. A 20-gauge Teflon intravenous cannula was inserted into a forearm vein, and a baseline blood sample drawn for a quantitative parasite count and parasite staging. The parasite counts and axillary temperature were measured at 0, 4, 8, 12, 16, 20, and 24 h posttreatment and then every 6 h until clearance of the parasites (defined as <1 parasite per 200 white blood cell nuclei on a thick film). The hematocrit was measured every 12 h. The microscopist was blinded to the treatment group.

Patients were randomized by use of a computer generated randomization table (in groups of 10) to receive a single oral dose of either 0, 25, 50, 75, 100, 150, 200, or 250 mg of artesunate (Guilin No. 1 Factory, Guangxi, People's Republic of China), i.e., from half a tablet to five tablets. 

The randomization code was revealed after patients had been admitted to the study, and the analysis was on an intention-to-treat basis. Patients were also given oral paracetamol (15 mg/kg), and after 1 h they were given a single oral dose of mefloquine (15 mg/kg; Mephaquine, Mepha, Basel, Switzerland). After 12 h they were given a further 10-mg/kg dose of mefloquine (total dose, 25 mg of base/kg). A single blood sample for a drug level was taken after 2 h. All patients were followed up for 28 days.

Precautions/Warnings

Take special care with artesunate prostate cancer tablets:

If you have experienced rash or urticarial reaction to artesunate before, you should not be treated with Artesunate 50 mg tablets, if avoidable, since this has been associated with recurrence of symptoms and occasionally with the development of severe allergic reactions.

Since the use of artesunate has not been evaluated for the following conditions, Artesunate 50 mg tablets is NOT recommended:

• ·         for the treatment of complicated malaria.
• ·         for treatment of malaria due to other types of parasites (Plasmodium vivax, Plasmodium malariae or Plasmodium ovale).
• ·         for prevention of malaria.

Artesunate tablets has not been studied specifically in patients with special hereditary disorders of the blood called thalassaemia, sickle cell anaemia and G6PD deficiency.

Pharmacology

Artesunate 50 mg tablets is an antimalarial agent, available in oral, rectal and parenteral formulations, that provides a rapid clinical effect in patients with Plasmodium falciparum malaria. The rapidity of effect, availability of an intravenous and intramuscular formulation and convenient dosage regimen make artesunate an ideal candidate for the treatment of severe malaria, including cerebral disease.While some results have been promising, there is no clear evidence to date that artesunate reduces mortality in patients with cerebral malaria to any greater extent than standard quinine therapy. When given as monotherapy, treatment should be continued for at least 5 to 7 days to prevent recrudescence.

Combination therapy with mefloquine allows artesunate to be administered over 3 days or less, with a satisfactory clinical outcome maintained. Although optimal dosages remain to be determined, this combination continues to provide the rapid onset of clinical effect observed with artesunate monotherapy, but decreases the rate of recrudescence to 2% (i.e., radical cure rate of 98%) when used as treatment in patients with uncomplicated malaria from areas with a high risk of multidrug-resistance falciparum malaria.

Although assessment of tolerability is complicated by the difficulty of distinguishing between disease and treatment-related events, artesunate drug bank and artesunate-mefloquine combinations appear to be well tolerated in adults and children. Indeed, it is possible that prior administration of artesunate may reduce the incidence of mefloquine-induced vomiting.

Clinical findings to date have not revealed any pattern of resistance to artesunate after use of the drug. However, given the history of the development of resistance to other antimalarial drugs, the use of artesunate should be restricted to areas of multidrug resistance, the drug should be used in combination with a longer acting agent such as mefloquine, and it should be used in regimens that provide radical cure rates of 90 to 100%. If used according to these treatment principles, artesunate will provide a well tolerated and valuable addition to the current extremely limited treatment options for multidrug-resistant falciparum malaria, a widespread parasitic disease associated with considerable mortality.

Storage/Handling Recommendations

Keep out of the reach and sight of children.

Do not store above 30ºC, Store in the original packaging

Buy Now : Buy Artesunate50mg Online